Partnering

In-licensing

In-licensing has historically played an important role at Soligenix. The rights to orBec®/oral BDP, and RiVax™ were in-licensed into Soligenix since 2002. Our strategy is to continue to build and diversify our pipeline of products in our core competencies.

We continue to seek new technologies/opportunities in the areas listed below. We will look at opportunities at all stages of development with an emphasis on later clinical stage opportunities. We would seek a minimum of US commercial rights with regard to any particular opportunity.

Examples of indications of interest are listed below:

HSC Transplant

  • GVHD
  • Mucositis
  • Venous occlusive disease
  • Conditioning regimens

Supportive Cancer Care

  • Mucositis
  • Cachexia

Gastrointestinal

  • Inflammatory conditions of the GI tract

Biodefense and Infectious diseases

  • Vaccines against bioterror threats
  • Therapeutics for treatment of biological and radiological exposure
  • Ant-infectives

Please direct inquiries to:

Evan Myrianthopoulos, Senior Vice President and Chief Financial Officer
Soligenix, Inc.
29 Emmons Drive - Suite C-10
Princeton, NJ 08540
Phone: (609) 538-8200
Fax: (609) 452-6467
E-mail: emyrian@soligenix.com